Recorded Incidence of Ursodeoxycholic Acid Side Effects
Ursodeoxycholic acid (UDCA) is generally well-tolerated with gastrointestinal side effects being most common, occurring in approximately 20-40% of patients, though most are mild and rarely require discontinuation.
Common Side Effects (≥5% Incidence)
Based on FDA-approved labeling data, the most frequently reported adverse events include 1:
Gastrointestinal Effects (Most Common)
- Diarrhea: 20-27% - the most common side effect
- Abdominal pain: 6-43% (varies by indication)
- Nausea: 13-17%
- Constipation: 9-26% (particularly in gallstone prevention)
- Dyspepsia: 11-17%
- Vomiting: 7-14%
- Flatulence: 5-8%
Non-Gastrointestinal Effects
- Headache: 18-25%
- Upper respiratory tract infections: 11-16%
- Viral infections: 9-26%
- Fatigue: 5-10%
- Back pain: 6-12%
- Dizziness: 13-17% (in gallstone prevention)
- Alopecia: 2-5%
Important Clinical Context
The incidence rates vary significantly based on the indication and dosing 1:
- Gallstone dissolution (8-10 mg/kg/day): Lower overall side effect rates
- Gallstone prevention (600 mg/day): Higher rates of constipation (26%) and diarrhea (25%)
Rare but Serious Adverse Events
Post-marketing surveillance has identified unexpected serious adverse events 2:
- Interstitial lung disease (rare)
- Pancytopenia (rare)
- Decompensation of liver cirrhosis in end-stage primary biliary cirrhosis 3
- Recurrent right upper quadrant pain (occasional) 3
Key Safety Points
Diarrhea occurs in less than 1% of patients at a severity requiring discontinuation 4. When it does occur, it is typically transient and dose-related 3.
Liver function tests remain normal during therapy, even with treatment durations extending up to 12 years 5. This is particularly important because UDCA's 7β-hydroxy group resists bacterial dehydroxylation, minimizing formation of hepatotoxic lithocholic acid 4.
Skin reactions are rare and typically due to drug adjuvants rather than UDCA itself 3.
Drug Interactions Affecting Tolerability
UDCA absorption is impaired by 3:
- Cholestyramine, colestimide, colestipol
- Aluminum hydroxide
- Smectite
These should be separated by at least 2 hours to avoid reduced efficacy.
Long-Term Safety Profile
UDCA demonstrates excellent long-term safety with no significant adverse effects reported even after 4-12 years of continuous therapy 5. A comprehensive pharmacovigilance study analyzing 1,651 adverse events from the FAERS database (2004-2023) confirmed that gastrointestinal side effects predominate, with no unexpected safety signals requiring hospitalization or ICU admission 2, 6.